For future public health emergencies, the Centers for Medicare & Medicaid Services should improve how it sets Medicare rates for clinical diagnostic laboratory tests under the Clinical Laboratory Fee Schedule and communicates with stakeholders involved in setting the rates, the Department of Health and Human Services’ Office of Inspector General advised last week. When CMS was working to increase testing capacity during the COVID-19 PHE, CMS’s standard rate setting procedures did not allow Medicare Administrative Contractors to set rates that were adequate to cover the cost of conducting COVID-19 viral tests for all laboratories, OIG said. In addition, OIG said CMS may have missed opportunities to obtain important information from laboratory associations and MAC pricing coordinators when it made decisions about the new CDLT rates.

Related News Articles

Headline
The AHA submitted a statement Sept. 17 for a House Ways and Means Committee markup session on a series of health care and other bills. Specifically, the AHA…
Headline
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
The AHA Sept. 15 urged Aetna to rescind its recently announced “level of severity inpatient payment” policy, saying that it “could erode the transparency…
Perspective
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
Speakers interested in leading conversations and collaborations at the AHA’s new Healthier Together Conference are advised to submit a content proposal by Sept…
Headline
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…